UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Click here for more information about laboratory operations and procedures

If you have additional questions regarding this test, please call: 415-353-1667

Search Our Test Menu


Item Value
Approval req'd? No
Available Stat? No
Test code MOLT (Order in Apex as 'Miscellaneous Outside Lab Test' using the complete test name above)
Test group AML molecular markers
Performed by Quest or ARUP
Sendout? Yes
Method PCR, sequencing
Container type Lavendar top vacutainer
Amount to Collect
EDTA whole blood 5 mL
Bone marrow aspirate in EDTA 3 mL
Sample type EDTA whole blood or bone marrow aspirate

Note: If blood or marrow aspirate is not available formalin fixed paraffin embedded tissue can be submitted
Preferred volume
EDTA whole blood 5 mL
Bone marrow aspirate in EDTA 3 mL
Min. Volume
EDTA whole blood 1 mL
Bone marrow aspirate in EDTA 1 mL
Processing notes Do not freeze whole blood. Ship whole blood at room temp or 4 degrees C. Order Quest test code # 19961 or ARUP test code # 2002437.
Normal range Negative for mutations of exons tested.
Synonyms c-KIT; Mast/stem cell growth factor receptor; SCFR; proto-oncogene c-Kit; tyrosine-protein kinase; CD117
Stability Room temperature 1 week, refrigerated 2 weeks
Turn around times 2 weeks
Additional information c-KIT Mutation analysis has been shown to have prognostic significance in acute myeloid leukemia (AML) containing mutations of the core factor binding protein. In addition, activating c-kit mutations have been indentified in various other human cancers. C-kit exon 8 and 17 mutations have been described in patients with CBF-AMLs and usually confer a poor prognosis with increased relapse rate. C-kit exon 9, 11, 13, 17 mutations have been reported in nearly 90% GIST patients. The presence mutation usually predicts poor survival. C-kit exon 17 mutation (D has been reported in patients with systemic mastocytosis.

In this assay, DNA is chosen as a starting material for detection of c-kit mutations. Because this assay relies on sequencing methodology, it should be performed on diagnostic specimens in which percent involvement is high, so optimally at diagnosis. (Sequencing assay methodology requires ~20% involvement for mutation detection). This assay is not appropriate for detection of minimal residual disease.
CPT coding 83891-90, 83892-90, 83898-90, 83904-90, 83909-90, 83912-90
Last Updated 10/6/2014 3:29:59 PM
Entry Number 1361
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center